Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 13
Submit an article Journal homepage
137
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

FLAI induction regimen in elderly patients with acute myeloid leukemia

Marco CerranoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; ;Department of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1666-3100
ORCID Icon,
Anna CandoniDivision of Hematology and SCT, University of Udine, Udine, Italy;
,
Elena CrisàDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; ;Department of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy;
,
Maria Vittoria DubbiniDivision of Hematology and SCT, University of Udine, Udine, Italy;
,
Stefano D’ArdiaDepartment of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy;
,
Maria Elena ZannierDivision of Hematology and SCT, University of Udine, Udine, Italy;
,
Mario BoccadoroDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; ;Department of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy;
,
Ernesta AudisioDepartment of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy;
,
Benedetto BrunoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; ;Department of Oncology, SSD Trapianto Allogenico, AOU Città della Salute e della Scienza di Torino, Turin, Italy
&
Dario FerreroDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; ;Department of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy;
show all
Pages 3339-3340 | Received 28 Jan 2019, Accepted 11 May 2019, Published online: 04 Jun 2019

References

  • Dombret H, Itzykson R. How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematol Am Soc Hematol Educ Program. 2017;2017:45–53.
  • Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997;99:939–944.
  • Westhus J, Noppeney R, Dührsen U, et al. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2018;60:1014–1022.
  • Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360–3368.
  • Russo D, Malagola M, Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol. 2005;131:172–179.
  • Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. Am J Hematol. 2013;88:10–15.
  • Clavio M, Gatto S, Beltrami G, et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. Leuk Lymphoma. 2001;40:305–313.
  • Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684–2692.
  • Ferrero D, Crisà E, Marmont F, et al. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Ann Hematol. 2014;93:1391–1400.
  • Candoni A, Papayannidis C, Martinelli G, et al. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial. Am J Hematol. 2018;93:655–663.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.